Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Medicinas Complementares
Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Sci Rep ; 10(1): 19116, 2020 11 05.
Artigo em Inglês | MEDLINE | ID: mdl-33154422

RESUMO

Various respiratory viral infections in general and seasonal influenza in particular may increase the susceptibility to bacterial infections. Plague caused by Yersinia pestis endangers large populations during outbreaks or bioterrorism attacks. Recommended antibiotic countermeasures include well-established protocols based on animal studies and corroborated by effective treatment of human cases. Until now, prior exposure to viral respiratory infections was not taken into consideration when selecting the appropriate treatment for plague. Here, we show that as late as 25 days after exposure to influenza virus, convalescent mice still exhibited an increased susceptibility to sublethal doses of Y. pestis, presented with aberrant cytokine expression, and impaired neutrophil infiltration in the lungs. Increased levels of M2 alveolar macrophages and type II epithelial cells, as well as induction in metalloproteases expression and collagen and laminin degradation, suggested that the previous viral infection was under resolution, correlating with enhanced susceptibility to plague. Surprisingly, postexposure prophylaxis treatment with the recommended drugs revealed that ciprofloxacin was superior to doxycycline in mice recovering from influenza infection. These results suggest that after an influenza infection, the consequences, such as impaired immunity and lung tissue remodeling and damage, should be considered when treating subsequent Y. pestis exposure.


Assuntos
Antibacterianos/uso terapêutico , Infecções por Orthomyxoviridae/complicações , Peste/tratamento farmacológico , Yersinia pestis , Animais , Antibacterianos/administração & dosagem , Ciprofloxacina/administração & dosagem , Ciprofloxacina/uso terapêutico , Suscetibilidade a Doenças , Doxiciclina/administração & dosagem , Doxiciclina/uso terapêutico , Pulmão/efeitos dos fármacos , Pulmão/microbiologia , Macrófagos Alveolares/efeitos dos fármacos , Camundongos , Infiltração de Neutrófilos/efeitos dos fármacos , Peste/complicações , Resultado do Tratamento
2.
Sci Rep ; 6: 35598, 2016 12 16.
Artigo em Inglês | MEDLINE | ID: mdl-27982031

RESUMO

Dysregulated activity of A Disintegrin And Metalloproteinase 17 (ADAM17)/TNFα Converting Enzyme (TACE) is associated with inflammatory disorders and cancer progression by releasing regulatory membrane-tethered proteins like TNFα, IL6R and EGFR ligands. Although specific inhibition of TACE is thought to be a viable strategy for inflammatory disorders and for malignancies treatment, the generation of effective inhibitors in vivo has been proven to be challenging. Here we report on the development of a protein inhibitor that leverages the endogenous modulator of TACE. We have generated a stable form of the auto-inhibitory TACE prodomain (TPD), which specifically inhibits in vitro and cell-surface TACE, but not the related ADAM10, and effectively modulated TNFα secretion in cells. TPD significantly attenuated TACE-mediated disease models of sepsis, rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), and reduced TNFα in synovial fluids from RA patients. Our results demonstrate that intervening with endogenous ADAM sheddase modulatory mechanisms holds potential as a general strategy for the design of ADAM inhibitors.


Assuntos
Proteína ADAM17/química , Artrite/tratamento farmacológico , Colite/tratamento farmacológico , Inibidores Enzimáticos/administração & dosagem , Choque Séptico/tratamento farmacológico , Proteína ADAM10/metabolismo , Proteína ADAM17/antagonistas & inibidores , Animais , Artrite/induzido quimicamente , Artrite/metabolismo , Células Cultivadas , Colite/induzido quimicamente , Colite/metabolismo , Colágeno/efeitos adversos , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Inibidores Enzimáticos/química , Inibidores Enzimáticos/farmacologia , Células HEK293 , Humanos , Lipopolissacarídeos/efeitos adversos , Macrófagos/citologia , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Macrófagos/patologia , Camundongos , Domínios Proteicos , Choque Séptico/induzido quimicamente , Choque Séptico/metabolismo , Ácido Trinitrobenzenossulfônico/efeitos adversos
3.
Phytochemistry ; 69(14): 2586-92, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18829053

RESUMO

Pectin methyl esterases (PMEs) and their endogenous inhibitors are involved in the regulation of many processes in plant physiology, ranging from tissue growth and fruit ripening to parasitic plant haustorial formation and host invasion. Thus, control of PME activity is critical for enhancing our understanding of plant physiological processes and regulation. Here, we report on the identification of epigallocatechin gallate (EGCG), a green tea component, as a natural inhibitor for pectin methyl esterases. In a gel assay for PME activity, EGCG blocked esterase activity of pure PME as well as PME extracts from citrus and from parasitic plants. Fluorometric tests were used to determine the IC50 for a synthetic substrate. Molecular docking analysis of PME and EGCG suggests close interaction of EGCG with the catalytic cleft of PME. Inhibition of PME by the green tea compound, EGCG, provides the means to study the diverse roles of PMEs in cell wall metabolism and plant development. In addition, this study introduces the use of EGCG as natural product to be used in the food industry and agriculture.


Assuntos
Camellia sinensis/química , Hidrolases de Éster Carboxílico/antagonistas & inibidores , Hidrolases de Éster Carboxílico/metabolismo , Catequina/análogos & derivados , Chá/química , Catequina/metabolismo , Citrus/enzimologia , Fluorometria , Solanum lycopersicum/enzimologia , Extratos Vegetais/metabolismo , Especificidade por Substrato
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA